United States · Platforms & data · Briefing.com

Disc Medicine Surges as Phase 3 APOLLO Trial Meets All Primary and Secondary Endpoints (IRON)

Published by Briefing.com · United States 12 d ago

Disc Medicine (IRON) is surging today after announcing that its pivotal Phase 3 APOLLO trial of bitopertin met both co-primary and all secondary endpoints in patients with…

Read the full article on Briefing.com Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.briefing.com)

Also worth reading

MarketBeat

Sampo PLC (OTCMKTS:SAXPY) Stock Short Interest Declines 48.8%

The Motley Fool

Golden Dome Is a $185 Billion Program, but Anduril Is Private. Here Are the 3 Public Companies Building It.

Benzinga

Disc Medicine Surges as Phase 3 APOLLO Trial Meets All Primary and Secondary Endpoints (IRON)

Share

Also worth reading

Sampo PLC (OTCMKTS:SAXPY) Stock Short Interest Declines 48.8%

Golden Dome Is a $185 Billion Program, but Anduril Is Private. Here Are the 3 Public Companies Building It.

Best Tech Stocks Right Now

Talking Costco: Why a special dividend might not be the right play

Beam Therapeutics surges 64% after InvestingPro’s undervalued call

Grand Theft Callout: ‘GTA 6’ fans are missing work on the game’s release day because they ‘don’t want to wait’ anymore